All News

11 July 2011

Micromet Announces Solid Tumor BiTE Antibody Collaboration with AmgenAntibodies

11 July 2011

Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada (*)) in Multiple SclerosisAntibodies

8 July 2011

Baxter and Halozyme Announce Top-Line Results of Phase III Study of HyQ in Patients with Primary ImmunodeficiencyAntibodies

7 July 2011

Phase 3 Trial of ZALTRAP (aflibercept) in Advanced Prostate Cancer to Continue as Planned at Recommendation of Independent Data Monitoring CommitteeAntibodies

6 July 2011

Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement for an Investigational Immuno-Oncology BiologicAntibodies

6 July 2011

Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone LossAntibodies

6 July 2011

biOasis Announces Transcend Vector Results With a Therapeutic Antibody That Targets Metastatic Breast CancerAntibodies

30 June 2011

Roche provides update from FDA hearing on Avastin for metastatic breast cancerAntibodies

30 June 2011

Ablynx Initiates a Phase I Study for Alx-0651, the First Nanobody in Clinical Development Targeting a GpcrAntibodies

29 June 2011

EYLEA (aflibercept injection) Submitted in Japan for Marketing Authorization for the Treatment of Wet Age-Related Macular DegenerationAntibodies

29 June 2011

UCB to Launch Research Alliance With Harvard UniversityAntibodies

28 June 2011

Morphotek, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung CancerAntibodies

28 June 2011

Two Pivotal Phase III Lucentis Studies Showed Patients With Diabetic Macular Edema Experienced Significant Improvements in Vision and Fewer Developed More Advanced RetinopathyAntibodies

28 June 2011

The Lancet Publishes Data from Protege, MacroGenics’ Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes PatientsAntibodies

27 June 2011

XOMA Discovers Two New Classes of Insulin Receptor-Regulating AntibodiesAntibodies

27 June 2011

Amgen Submits Application to Expand Indication for XGEVA (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the BoneAntibodies

27 June 2011

Millennium Announces EMA Acceptance of Marketing Authorization Application for ADCETRIS (Brentuximab Vedotin)Antibodies

24 June 2011

iCo Therapeutics Executes Bertilimumab License with Immune PharmaceuticalsAntibodies

24 June 2011

Baxter Receives Positive Opinion for IVIG Therapy in Europe for Treatment of Multifocal Motor NeuropathyAntibodies

24 June 2011

Genmab Announces Zalutumumab UpdateAntibodies

24 June 2011

Amgen Receives Positive CHMP Opinion for Vectibix (Panitumumab) in Combination With ChemotherapyAntibodies

22 June 2011

European Commission Approves Inclusion of Anti-JC Virus Antibody Status as a PML Risk Factor in TYSABRI LabelingAntibodies

21 June 2011

Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune DiseasesAntibodies

21 June 2011

Compugen Announces Initial Validation of Additional B7/CD28 Protein Family Based Product CandidateAntibodies

20 June 2011

Alexion Initiates Clinical Trial of Eculizumab as a Potential Treatment for Patients with STEC-HUS in Expanded Response to EHEC Crisis in GermanyAntibodies

20 June 2011

Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6Antibodies

17 June 2011

Immune System Therapeutics Limited Drug Shows Positive Response in Patients with Multiple Myeloma Blood CancerAntibodies

17 June 2011

Regeneron Announces EYLEA (aflibercept ophthalmic solution) Receives Unanimous Recommendation for Approval for Treatment of Wet AMD from FDA Advisory CommitteeAntibodies

16 June 2011

FDA approves Nulojix for kidney transplant patientsAntibodies

16 June 2011

Seattle Genetics Announces FDA Advisory Committee to Review Brentuximab Vedotin for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCLAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Ranibizumab (Lucentis) Biosimilars Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

EpCAM-Targeted Antibodies Pipeline Review

c-Met-Targeted Antibody Therapy Pipeline Review